{"entity":{"id":"nct05770102","kind":"trial","name":"DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi","aka":["DETERMINE"],"tldr":"A phase 2/3 trial of atezolizumab in colorectal cancer, run by Cancer Research UK, now recruiting.","summary":"DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition is a phase 2/3, interventional study registered as NCT05770102 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2023-10-25 and due to reach its primary completion in 2029-10. Interventions recorded: Atezolizumab. Conditions listed: Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Colorectal Neoplasms; Endometrial Neoplasms; Melanoma; Solid Tumours. Primary outcome: Objective Response (OR); Durable Clinical Benefit (DCB). Sites: United Kingdom. United Kingdom sites listed: 27. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05770102","url":"https://clinicaltrials.gov/study/NCT05770102"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Belfast City Hospital (Belfast); University Hospital Birmingham (Birmingham); Birmingham Children's Hospital (Birmingham); Bristol Royal Hospital for Children (Bristol); Bristol Haematology and Oncology Centre (Bristol); Addenbrooke's Hospital (Cambridge); Velindre Cancer Centre (Cardiff); Cardiff Children's Hospital (Cardiff); Western General Hospital (Edinburgh); The Beatson Hospital (Glasgow); Royal Hospital for Children Glasgow (Glasgow); Leicester Royal Infirmary (Leicester) and 15 more."],"nct":"NCT05770102","phase":"2/3","setting":"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.","sponsor":"Cancer Research UK","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05770102/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}